Drug updated on 4/24/2024
| Dosage Form | Cream (topical; 1%) |
| Drug Class | Antifungals |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.
Summary
- Luliconazole (Luzu) is recommended for the topical management of interdigital tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum and Epidermophyton floccosum in individuals 18 years of age and older.
- Two systematic reviews/meta-analyses focused on the efficacy and safety of luliconazole compared to other treatments such as ciclopirox 8% lacquer, efinaconazole 10% solution, tavaborole 5% solution, and others were analyzed.
- The comparison of safety profiles based on low-quality evidence suggests that there may be little to no difference in adverse events between luliconazole and its comparator, with common adverse events including dry skin, paronychia, eczema, and hyperkeratosis, which improved or resolved after treatment.
- There is uncertainty regarding whether luliconazole leads to higher rates of complete cure due to the very low quality of evidence, making direct comparisons difficult. However, moderate-to-high quality evidence supports the efficacy of efinaconazole and tavaborole solutions in achieving complete cure, suggesting they might offer an advantage over luliconazole.
- When combined with CO2 laser therapies in a combination therapy approach rather than through direct comparisons with other treatments, the efficacy of luliconazole could be significantly enhanced, suggesting its substantial value, especially in treating moderate to severe cases.
- The research primarily focuses on adult populations aged from an average range of 27 to 68 years old, with more than one toenail affected by mild to moderate onychomycosis without matrix involvement, providing critical information regarding the generalizability of findings across broader population groups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Luzu (luliconazole) Prescribing Information. | 2020 | Bausch Health US LLC, Bridgewater, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The effects of CO2 laser and topical agent combination therapy for onychomycosis: a meta-analysis. | 2021 | Dermatologic Therapy |
| Topical and device-based treatments for fungal infections of the toenails. | 2020 | The Cochrane Database of Systematic Reviews |